Tango Therapeutics to present updated vopimetostat combination trial data at ESMO 2026

TNGX•2026-10-16

Tango Therapeutics will present updated Phase 1/2 vopimetostat combination data at the ESMO Congress in Madrid on Oct. 25, 2026, and hold a pancreatic cancer-focused investor webcast on Oct. 23.

1. Trial data presentation

The study evaluates vopimetostat with daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant metastatic pancreatic cancer or non-small cell lung cancer. The investor webcast is scheduled for Oct. 23 at 7:30 a.m. ET.

Tango Therapeutics to present updated vopimetostat combination trial data at ESMO 2026

1. Trial data presentation

Related News

Ironwood Pharmaceuticals appoints Tammi Gaskins as chief executive officer

Organon reports positive six-year interim Phase 3 results for Miudella IUD

Rhythm Pharmaceuticals, Inc.: William Blair initiates coverage with outperform rating

Varonis Systems: Rosenblatt Securities cuts to neutral from buy, lowers target price to $49.75 from $55

Charles Schwab target price cut by Deutsche Bank to $125 from $130